RT Journal Article
T1 Monkeypox in humans: a new outbreak
A1 Martín Delgado, Mari Cruz
A1 Martín Sánchez, Francisco Javier
A1 Martínez-Sellés D Oliveira Soares, Manuel
A1 Molero García, José María
A1 Moreno Guillén, Santiago
A1 Rodríguez Artalejo, Fernando
A1 Ruiz Galiana, Julián
A1 Cantón Moreno, Rafael María
A1 Lucas Ramos, Pilar De
A1 García Botella, Alejandra María
A1 García Lledó, Alberto
A1 Hernández-Sampelayo Matos, Teresa
A1 Gómez Pavón, Javier
A1 González Del Castillo, Juan María
A1 Muñoz García, Patricia Carmen
A1 Valerio Minero, Maricela
A1 Catalán Alonso, Pilar
A1 Burillo Albizua, Almudena
A1 Cobo, Alejandro
A1 Alcamí, Antonio
A1 Bouza Santiago, Emilio
AB Infection caused by Monkeypox Virus (MPVX) has small rodents as its natural reservoir and both monkeys and humans are occasional hosts. The causative agent is an Orthopoxvirus (MPVX) that was isolated in monkeys in 1958 and proved capable of passing to humans in 1970. It remained contained in Africa, causing isolated episodes of infection, until 2003 when an outbreak occurred in the United States following importation of animals from that continent. Since then, anecdotal cases have continued to be reported outside Africa, usually very clearly linked to travelers to those countries, but in May 2022, a broad outbreak of this disease has begun, now affecting several continents, with the emergence of human cases of MPVX (H-MPVX) infection mainly among Men that have Sex with Men (MSM). The disease has an incubation time ranging from 5 to 15 days and is characterized by the presence of pustules, fever, malaise and headache. The presence of significant regional lymphadenopathy is a differential feature with episodes of classical smallpox. Proctitis and pharyngitis, with minimal skin lesions, may be another form of presentation. Diagnosis can be confirmed by PCR testing of lesions or by demonstration of MPVX in other body fluids or tissues, although in the appropriate epidemiologic setting the clinical picture is highly suggestive of the disease. Effective drug treatment has been developed as part of programs to protect against potential bioterrorist agents and smallpox vaccinees are known to have high protection against monkeypox. New vaccines are available, but neither the drugs nor the vaccines are yet freely available on the market. The prognosis of the disease appears, at least in adults in developed countries, to be good, with very low mortality figures and much less aggressive behavior than that described in classical smallpox. Isolation measures, essential for the control of the outbreak, have been published by the health authorities.
PB Sociedad Española de Quimioterapia
SN 0214-3429
SN 1988-9518
YR 2022
FD 2022-07-06
LK https://hdl.handle.net/20.500.14352/130185
UL https://hdl.handle.net/20.500.14352/130185
LA eng
NO Martín-Delgado, M. C., Martín Sánchez, F. J., Martínez-Sellés, M., Molero García, J. M., Moreno Guillén, S., Rodríguez-Artalejo, F. J., Ruiz-Galiana, J., Cantón, R., De Lucas Ramos, P., García-Botella, A., García-Lledó, A., Hernández-Sampelayo, T., Gómez-Pavón, J., González Del Castillo, J., Muñoz, P., Valerio, M., Catalán, P., Burillo, A., Cobo, A., Alcamí, A., … Bouza, E. (2022). Monkeypox in humans: a new outbreak. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 35(6), 509–518. https://doi.org/10.37201/req/059.2022
DS Docta Complutense
RD 20 ene 2026